All compounds

BPC-157

Also sold as body protection compound 157, pentadecapeptide BPC 157, PL 14736. Synthetic 15-amino-acid peptide.

Largely unknown (3 of 5)

BPC-157 has an impressive-looking body of research behind it, almost all of it in rats, much of it from a single laboratory, and essentially none of it in humans — so the honest answer to whether it works, or whether it is safe, is that nobody knows.

What it is

BPC-157 is a synthetic peptide fifteen amino acids long. It is described as a fragment of a protein found in human gastric juice — “body protection compound” — though the parent protein and the derivation are less firmly established than that description implies.

It is sold online in small glass vials of powder that the buyer mixes and injects, and increasingly as capsules and nasal sprays. It has never been approved as a medicine anywhere in the world. Unlike cardarine or ostarine, there is no story of a pharmaceutical company running trials and walking away, because there was never a full development programme to walk away from.

BPC-157 is on this site for a specific reason, and it is not that we think it is dangerous. It is the clearest example of a compound where the honest answer is that nobody knows — and where a great deal of confident writing exists in both directions that is not supported by anything.

What it actually does

The proposed mechanism is that BPC-157 promotes healing by encouraging the formation of new blood vessels — angiogenesis — and by influencing growth factor signalling and nitric oxide pathways in injured tissue.

People take it for tendon and ligament injuries that are not healing, for gut problems including inflammatory bowel disease, and after surgery. The reason it has the reputation it has is that in animal experiments the results are striking: severed tendons reattaching, damaged gut healing, injuries recovering faster than they should.

The honest position on the experience of taking it: many people report it helped, sometimes dramatically. That report is real and we are not dismissing it. It is also exactly what you would expect to hear about a treatment taken for injuries that were going to improve anyway, on a timescale nobody measured, without a control group. Tendon injuries heal slowly and unevenly, which makes them close to the worst possible condition for judging a treatment from personal experience.

What the evidence actually shows

In animals: a large and genuinely interesting body of work. Dozens of rodent studies report accelerated healing of tendon, muscle, bone, gut, and nerve, together with protective effects in a striking range of injury models.

Two things about that literature matter, and neither is a criticism of the researchers.

The first is that an unusually large proportion of it comes from a single research group and its collaborators. That is not evidence of anything improper — it is common for a compound nobody else has taken up. It does mean the usual protection of independent replication by unrelated labs, using different models and different hands, is largely absent. In a field where independent replication frequently fails, that is a real limitation on how much weight the volume of papers can carry.

The second is that the range of claimed effects is very wide. A compound reported to help tendons, gut, brain, blood vessels, liver and nerve is either a genuinely fundamental healing mechanism or a signal that the models are picking up something non-specific. Both remain possible.

In humans: essentially nothing. There is no completed randomised controlled trial demonstrating that BPC-157 heals a tendon, or a gut, or anything else, in a person. An oral form was investigated for inflammatory bowel disease some years ago and did not lead to an approved product. The reviews you will find are reviews of animal work.

This is the entire finding, and it deserves to be stated without softening: the human efficacy evidence for BPC-157 is not weak. It is absent.

On safety: also absent, in the same way. There are no published reports of serious harm from BPC-157 — but that is what you would expect for a compound with no clinical trials, no pharmacovigilance system, and no mechanism by which a problem would be recorded and connected back. Animal studies have not shown toxicity, which is genuinely reassuring as far as it goes, which is not far.

The specific unknown worth naming: BPC-157’s proposed mechanism is promoting new blood vessel growth. That is exactly the effect you want in a healing tendon. It is also, in general, a thing tumours require in order to grow. There is no evidence that BPC-157 causes or accelerates cancer, and we are not implying there is. But a systemically administered angiogenesis promoter, used long-term, in humans, has not been studied at all — and if there were a problem of that kind, the current evidence base is not capable of detecting it.

The risk profile

Largely unknown (3 of 5) — Promising or popular, but the human evidence to judge it does not exist yet.

What going wrong looks like from the inside

BPC-157 has no known characteristic failure mode. No tolerance, no withdrawal, no escalation pattern, no organ that reliably complains. We would rather say that than invent a warning, and on this page it is the accurate answer.

But there is a real failure mode here, and it is not pharmacological.

It is that you cannot tell whether it is working, and the absence of a bad experience will feel like evidence. You take it for an injury. The injury gets better. You conclude it worked — and it may have, and you will never know, because tendon injuries get better on their own, slowly and unpredictably. There is no signal available to you from inside your own body that distinguishes “the peptide healed this” from “twelve weeks passed.”

The consequence that actually costs people something is delay. Someone with a tendon problem that needs proper assessment, load management, or in some cases surgery may spend months on an injectable peptide instead, because it feels like doing something. The injury does not improve, and the window where a straightforward intervention would have worked closes. That is the most likely way BPC-157 harms someone, and it has nothing to do with the molecule.

The other real risk is what is in the vial. You are buying an unregulated peptide from a vendor with no obligation to anyone, mixing it yourself, and injecting it. Analysis of custom synthetic peptides has found undeclared constituents. Injecting something prepared without sterile technique carries infection risk that is entirely independent of whether BPC-157 does anything at all — and abscesses at injection sites are a genuinely common outcome in this space.

Interactions and combinations

There is no known interaction profile, largely because there is no human pharmacology to build one from. BPC-157 is not a central nervous system depressant and does not carry the fatal-combination risk of the opioid and GABA compounds on this site.

The situation that deserves genuine caution is an active cancer diagnosis, or a history of one. Given the angiogenesis mechanism and the complete absence of human data, this is not a decision to make from a forum. It is a question for an oncologist, who will at least be reasoning about the right mechanism.

The same caution applies in pregnancy, for the ordinary reason that a compound with no human data has no human data in pregnancy either.

BPC-157 is prohibited in tested sport.

If you’re already using it

There is nothing to withdraw from. If you stop, nothing happens.

If you are using it for an injury, the useful question is not whether to continue but whether the injury has actually been assessed by someone who can tell you what is wrong with it. A peptide with no human evidence is a poor substitute for a diagnosis, and it is a very good way to spend three months not getting one.

If you are injecting it, the risks worth taking seriously are the ordinary ones: sterile technique, clean skin, never sharing anything, and treating redness, heat, swelling or a fever at an injection site as a reason to see someone rather than wait.

And if you believe it helped you — that is a legitimate thing to think, and it might be right. We are not telling you it did not work. We are telling you that nobody, including you, is currently in a position to know, and that anyone who tells you otherwise with confidence is going beyond the evidence in whichever direction suits them.

This page has not yet been reviewed by a clinician. It was written from the published literature and every claim is cited, but no named medical professional has checked it. We say so here rather than let a missing byline read as an implicit one.

Last reviewed 7 September 2026. Found something wrong? Corrections are published, not silently edited.